FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143554920> ?p ?o ?g. }

• W2143554920 endingPage "606" @default.
• W2143554920 startingPage "604" @default.
• W2143554920 abstract "Sir, Chronic idiopathic urticaria (CIU) is one of the most common skin diseases, affecting about 3% of the Western population. Although the symptoms of CIU are primarily due to mast cell degranulation and subsequent histamine release, treatment with H1 antihistamines is often insufficient. One explanation for this is that the actions of other mast cell mediator types have been overlooked, such as prostaglandins and thromboxanes, which display inflammatory properties similar to those of histamine. Prostaglandins and thromboxanes are formed from arachidonic acid by the actions of the enzymes cyclooxygenases (COXs), of which there are two isoforms, with the inducible COX‐2 being responsible for pseudoallergic and other inflammatory responses. Reasoning that COX‐2 might therefore be a relevant target in the treatment of urticaria we investigated the clinical efficacy of a combination therapy comprising the H1 antihistamine desloratadine and the selective COX‐2 inhibitor rofecoxib. Ten caucasian patients with CIU, in whom conventional therapy with H1 antihistamines did not resolve the symptoms, chose to undergo this experimental treatment. The diagnosis was based on the patients' history and extensive laboratory investigations to exclude underlying causes. Disease severity was assessed using a scoring system based on weal formation and pruritus according to a recent consensus publication.1 A patient was considered ‘clinically improved’ if their score (on a 0–6 scale) declined by a value of at least 2. The patients were initially treated with the H1 antihistamine desloratadine 2 × 5 mg daily for 4 weeks, followed by a combination treatment with desloratadine 2 × 5 mg and rofecoxib 25 mg daily for another 4 weeks." @default.
• W2143554920 created "2016-06-24" @default.
• W2143554920 creator A5021559096 @default.
• W2143554920 creator A5041025684 @default.
• W2143554920 creator A5049085425 @default.
• W2143554920 creator A5067814311 @default.
• W2143554920 creator A5071405016 @default.
• W2143554920 creator A5078531159 @default.
• W2143554920 date "2003-03-01" @default.
• W2143554920 modified "2023-10-17" @default.
• W2143554920 title "The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria" @default.
• W2143554920 cites W1959438171 @default.
• W2143554920 cites W2006531593 @default.
• W2143554920 cites W2064746705 @default.
• W2143554920 cites W2118748306 @default.
• W2143554920 cites W2150235211 @default.
• W2143554920 cites W2256824405 @default.
• W2143554920 cites W2318599684 @default.
• W2143554920 doi "https://doi.org/10.1046/j.1365-2133.2003.05209_12.x" @default.
• W2143554920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12653769" @default.
• W2143554920 hasPublicationYear "2003" @default.
• W2143554920 type Work @default.
• W2143554920 sameAs 2143554920 @default.
• W2143554920 citedByCount "11" @default.
• W2143554920 countsByYear W21435549202014 @default.
• W2143554920 crossrefType "journal-article" @default.
• W2143554920 hasAuthorship W2143554920A5021559096 @default.
• W2143554920 hasAuthorship W2143554920A5041025684 @default.
• W2143554920 hasAuthorship W2143554920A5049085425 @default.
• W2143554920 hasAuthorship W2143554920A5067814311 @default.
• W2143554920 hasAuthorship W2143554920A5071405016 @default.
• W2143554920 hasAuthorship W2143554920A5078531159 @default.
• W2143554920 hasConcept C1122143 @default.
• W2143554920 hasConcept C126322002 @default.
• W2143554920 hasConcept C181199279 @default.
• W2143554920 hasConcept C185592680 @default.
• W2143554920 hasConcept C203014093 @default.
• W2143554920 hasConcept C207480886 @default.
• W2143554920 hasConcept C2776785769 @default.
• W2143554920 hasConcept C2776880894 @default.
• W2143554920 hasConcept C2777361909 @default.
• W2143554920 hasConcept C2777628954 @default.
• W2143554920 hasConcept C2777995640 @default.
• W2143554920 hasConcept C2778582115 @default.
• W2143554920 hasConcept C2779689624 @default.
• W2143554920 hasConcept C2779726688 @default.
• W2143554920 hasConcept C2780581156 @default.
• W2143554920 hasConcept C2780664492 @default.
• W2143554920 hasConcept C2781025919 @default.
• W2143554920 hasConcept C2909278008 @default.
• W2143554920 hasConcept C2909530563 @default.
• W2143554920 hasConcept C55493867 @default.
• W2143554920 hasConcept C71924100 @default.
• W2143554920 hasConcept C89560881 @default.
• W2143554920 hasConcept C90924648 @default.
• W2143554920 hasConcept C98274493 @default.
• W2143554920 hasConceptScore W2143554920C1122143 @default.
• W2143554920 hasConceptScore W2143554920C126322002 @default.
• W2143554920 hasConceptScore W2143554920C181199279 @default.
• W2143554920 hasConceptScore W2143554920C185592680 @default.
• W2143554920 hasConceptScore W2143554920C203014093 @default.
• W2143554920 hasConceptScore W2143554920C207480886 @default.
• W2143554920 hasConceptScore W2143554920C2776785769 @default.
• W2143554920 hasConceptScore W2143554920C2776880894 @default.
• W2143554920 hasConceptScore W2143554920C2777361909 @default.
• W2143554920 hasConceptScore W2143554920C2777628954 @default.
• W2143554920 hasConceptScore W2143554920C2777995640 @default.
• W2143554920 hasConceptScore W2143554920C2778582115 @default.
• W2143554920 hasConceptScore W2143554920C2779689624 @default.
• W2143554920 hasConceptScore W2143554920C2779726688 @default.
• W2143554920 hasConceptScore W2143554920C2780581156 @default.
• W2143554920 hasConceptScore W2143554920C2780664492 @default.
• W2143554920 hasConceptScore W2143554920C2781025919 @default.
• W2143554920 hasConceptScore W2143554920C2909278008 @default.
• W2143554920 hasConceptScore W2143554920C2909530563 @default.
• W2143554920 hasConceptScore W2143554920C55493867 @default.
• W2143554920 hasConceptScore W2143554920C71924100 @default.
• W2143554920 hasConceptScore W2143554920C89560881 @default.
• W2143554920 hasConceptScore W2143554920C90924648 @default.
• W2143554920 hasConceptScore W2143554920C98274493 @default.
• W2143554920 hasIssue "3" @default.
• W2143554920 hasLocation W21435549201 @default.
• W2143554920 hasLocation W21435549202 @default.
• W2143554920 hasOpenAccess W2143554920 @default.
• W2143554920 hasPrimaryLocation W21435549201 @default.
• W2143554920 hasRelatedWork W1522526306 @default.
• W2143554920 hasRelatedWork W1985829268 @default.
• W2143554920 hasRelatedWork W1996134223 @default.
• W2143554920 hasRelatedWork W2001075005 @default.
• W2143554920 hasRelatedWork W2048102171 @default.
• W2143554920 hasRelatedWork W2135178084 @default.
• W2143554920 hasRelatedWork W2143554920 @default.
• W2143554920 hasRelatedWork W2240147013 @default.
• W2143554920 hasRelatedWork W2765857125 @default.
• W2143554920 hasRelatedWork W99442104 @default.
• W2143554920 hasVolume "148" @default.
• W2143554920 isParatext "false" @default.
• W2143554920 isRetracted "false" @default.

• next